Berkshire requires a 25–50% discount to intrinsic value before buying.
Buffett Quality Checklist
✗ROE >15% consistently (≥7 of last 10 years)
✓Free cash flow positive (≥8 of last 10 years)
✓Conservative leverage — Debt/Equity below 1
✗Revenue growing at CAGR >5%
✗EPS growing at CAGR >5%
10-Year Financial History — SEC EDGAR 10-K Filings
Year▲
Revenue▲
Net Income▲
FCF▲
Owner Earnings▲
ROE▲
Net Margin▲
LT Debt▲
Cash▲
2016
$52.8B
$7.2B
$14.4B
$11.1B
12.1%
13.7%
$31.4B
$2.6B
2017
$52.5B
$21.3B
$14.8B
$25.6B
29.9%
40.6%
$33.5B
$1.3B
2018
$40.8B
$11.2B
$13.8B
$15.6B
17.6%
27.3%
$32.9B
$1.1B
2019
$40.9B
$16.0B
$10.5B
$19.7B
25.4%
39.2%
$36.0B
$1.1B
2020
$41.7B
$9.2B
$12.2B
$11.6B
14.5%
22.0%
$4.0B
$1.8B
2021
$81.3B
$22.0B
$29.9B
$24.5B
28.5%
27.0%
$36.2B
$1.9B
2022
$101.2B
$31.4B
$26.0B
$33.2B
32.8%
31.0%
$32.9B
$416.0M
2023
$59.6B
$2.1B
$4.8B
$4.5B
2.4%
3.6%
$61.5B
$2.9B
2024
$63.6B
$8.0B
$9.8B
$12.1B
9.1%
12.6%
$57.4B
$1.0B
2025
$62.6B
$7.8B
$9.1B
$11.7B
9.0%
12.4%
$61.6B
$1.1B
Warren & Charlie
Buffett / Munger — quality, moat & valuation
PFIZER INC (PFE) — Investment Memo
🐂 The Bull Case (Warren's voice)
Let's be honest: this isn't a See's Candies. There is no "toll bridge" here, only a series of temporary gates.
The Infrastructure Play: Pfizer possesses a global distribution and regulatory machine that is nearly impossible to replicate. They don't just make drugs; they navigate the world's bureaucracies.
The "Buying Growth" Gamble: While buying innovation is expensive, the Seagen acquisition provides a foothold in oncology that could offset the COVID collapse. If these acquisitions hit, the scale of Pfizer turns linear growth into exponential profit.
The Dividend Floor: At current depressed prices, the yield is an aggressive attractor. If the business simply stops shrinking, the cash return is a compelling alternative to bonds.
Price of Admission: This becomes attractive only when the market prices it as a "dying" business, but the cash flows remain "healthy." We want it at a price where the dividend is essentially free money and the pipeline is a lottery ticket.
🐻 The Bear Case (Charlie inverts)
"Show me where I'll die and I won't go there." In Pfizer's case, the grave is dug with debt and expiring patents.
The Innovation Treadmill: Pfizer is trapped in a cycle of "Buy-to-Replace." They spend billions on acquisitions because their internal R&D is a failure. If the cost of buying innovation rises faster than the revenue those drugs produce, the business is a mathematical impossibility.
The Debt Spiral: Doubling debt to $61.6B while ROE crashes to 9.0% is an invitation to disaster. They are using leverage to mask a lack of organic growth. Interest payments don't care about "medical miracles."
Regulatory Guillotine: The Inflation Reduction Act and global price caps are eroding the "temporary monopoly" model. The era of pricing a drug at $100,000 just because you can is ending.
Most Likely Failure: The "Slow Bleed." Over the next 5–10 years, the patent cliffs outpace the acquisition integration, and Pfizer transforms from a growth engine into a legacy utility with a shrinking balance sheet.
💰 Valuation & Margin of Safety
The DCF reveals a business that the market is still treating as a giant, while the numbers describe a shrinking entity.
Intrinsic value estimate: $23.48 per share
25% margin of safety entry: $17.61(Conservative)
50% margin of safety entry: $11.74(Buffett's ideal)
Current Status: Expensive. Even at recent lows, the market is pricing in a recovery that the ROE and FCF trends do not support. We are paying for "hope," not "cash."
Verdict: PASS
The current price offers no margin of safety against a deteriorating ROE and mounting debt. The moat is a sieve, and the management is shopping with money they haven't earned. We do not buy "lottery tickets" when the house is charging us a premium.
Other Analyst Views· Lynch · Damodaran
Research Notes· Money Model · Moat · Financials · Management
Data sourced from SEC EDGAR XBRL filings (10-K only). For educational purposes — not investment advice.